Evolent Health (EVH) Stock Forecast & Price Target

Evolent Health is well positioned by the secular shift toward value-based care, with Medicare and Federal budget pressures, Medicare Advantage and managed Medicaid growth, and rising chronic illness supporting demand for its integrated specialty and population-health platform. Its 2Q26 update strengthened the case further: management raised 2026 adjusted EBITDA guidance to $120 million-$135 million, guided to roughly 25%+ revenue growth in 2027, and highlighted about $129 million of 2026 EBITDA and $151 million in 2027, aided by margin improvement and new-contract ramp. Near-term visibility also improved as Highmark drove about $140 million of the roughly $160 million sequential Performance Suite increase, while favorable oncology and cardiology trends, plus contractual prevalence adjustments, suggest earnings resilience and better monetization ahead.

Evolent Health is facing a structurally fragile outlook because its HCIT and value-based care demand can be derailed by government program slowdowns, tighter hospital budgets, facility consolidation, and intensifying price competition, all of which can suppress customer spending and delay non-EHR purchases. The company also has material execution risk from slower-than-expected client signings, existing clients switching vendors, and a value-based care shift that may progress more slowly with limited government support, which threatens guidance and margin maturation. Although payer rate and contract adjustments have helped offset elevated prevalence and acuity, the reliance on these corrections, combined with Medicaid exposure and potential utilization shocks, leaves the fundamentals vulnerable.